Although it had nic rip off support of a larger pattern with another test of the mid term downward resiatnce I am looking to potentially scoop some up. I really want to see how we react at this 7.60$ level holding as support. Might be worth a buy attempt. Targets of 10$+ howver the Key breakout level isn’t until we did suppprt above 8.05$. Therefor that’s the...
This is my top 10 estimates for the highs of the day on Monday (6/12/2021) according to my AI program and for those users that have been following my ai idea updates, I have improved the ai quite a bit to provide much more accurate results and I have implemented a scoring system that ranges from +30 to -30 and this is essentially the AI confidence that the...
If we hold, we have a double bottom in play. This could lead to filling the gap that has occurred. Look for institutions to treat this as the Demand zone. The recent sell off was the supply zone.
Curis Announces Positive Preliminary Data from Ongoing Phase 1 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Key findings include:
- Marrow blast reductions observed in all evaluable patients (6 patients).
- 6 of 7 patients enrolled remain on study.
- Patients enrolled experienced a...
Curis Announces Positive Preliminary Data from Ongoing Phase 1 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
1% CAPITAL
Curis skyrockets 448% after encouraging phase 1 data for leukemia treatment! BE CAREFUL here, this is a speculative play. I got a couple batches of shares. Do your own due diligence, your risk is 100% your responsibility. You win some or you learn some. Consider being charitable with some of your profit to help humankind. Small incremental steps work : If you...
CRIS: Curis, Inc.
2020-12-08 07:00:00
Curis Announces Positive Preliminary Data from Ongoing Phase 1 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
NASDAQ:CRIS
DISCLOSURE: II've been a long follower of CURIS since two years ago and experienced an abysmal loss last year because I got married with this stock. LOL.
Key fundamentals:
$17.5 million shares offering at $1.24 on June 12, 2020.
FDA clearance of IND application for CI-8993 on June 10, 2020 and the stock sky rocketed from .86c to $3.86 range...
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
NASDAQ
